Whereas HLA DR++ monocyte %leukocyte (OR=0.443, 95%CI:0.248-0.793, P=0.006), CD20 on IgD+ CD24+ B cell (OR=0.326, 95%CI:0.139-0.765, P=0.010), CD4 on HLA DR+ CD4+ T cell (OR=0.239, 95%CI:0.099-0.579, P=0.002), HLA DR on CD14+ CD16- monocyte (OR=0.69, 95%CI:0.543-0.876, P=0.002), HLA DR on CD14+ monocyte (OR=0.682, 95%CI:0.533-0.873, P=0.002), HLA DR on monocyte (OR=0.706, 95%CI:0.537-0.928, P=0.013), HLA DR on CD33+ HLA DR+ CD14- (OR=0.642, 95%CI:0.466-0.884, P=0.007) were related to a reduced risk of vulvar cancer. This evidence concerns the gene CD33 and vulva cancer.